Pioglitazone slowed coronary plaque progression and shrank necrotic core in diabetics
Data-rich overview of pioglitazone's effects on plaque. In PERISCOPE (543 type 2 diabetes patients with CAD, 18 months, IVUS) pioglitazone lowered percent atheroma volume while glimepiride raised it. A smaller trial (Ogasawara 2009) found reduced necrotic core and higher adiponectin, suggesting benefit via reduced inflammation.

